Open-market purchases of Nuvectis Pharma, Inc. (NVCT) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Marlio Charles Mosseri10% Owner | $916K | Added | |||
| Purchased June 30 via Emerald Hill Ventures SA at $18.32/share (range $18.29–$18.32). Now $19.63 (+7.2% since buy). Simultaneous cluster: CEO Ron Bentsur also bought 12,500 shares at $20.00 ($250K). Oncology biotech with recent public offering. | ||||||
| Jul 7, 2026 | Ron BentsurCEO | $250K | Added | |||
| CEO bought June 30 at exactly $20.00/share — likely tied to concurrent public offering at $20. Now $19.63 (-1.9%, slightly underwater). Part of NVCT cluster buy week alongside 10% owner Mosseri ($916K buy same day). | ||||||
| Jul 6, 2026 | Marlio Charles Mosseri10% Owner | $916K | Added | |||
| Bought Jun 30 at $18.32 avg (range $18.29–$18.32). Now $19.57 (+6.8%). Post-offering cluster buy alongside CEO Bentsur ($250K). Precision oncology biotech. Total insider cluster ~$1.17M. | ||||||
| Jul 6, 2026 | Ron BentsurChairman & CEO | $250K | Added | |||
| Bought at $20.00 (public offering price, Jun 29–Jul 1 window). Now $19.57 (-2.2%). Cluster buy alongside 10% owner Mosseri. Combined NVCT insider cluster = $1.17M. Note: may be offering-price buy (verify transaction code). | ||||||
| Jul 3, 2026 | Marlio Charles Mosseri10% Owner | $916K | Added | |||
| Purchased 50,000 shares at weighted avg $18.32 on June 30, 2026 — day after NVCT priced $100M public offering at $20.00. Buying below the offer price in open market signals conviction. Current price $19.57 (+6.8% from buy). Cluster buy: CEO also purchased same window. | ||||||
| Jul 3, 2026 | Ron BentsurChairman & CEO | $250K | Added | |||
| CEO bought 12,500 shares at $20.00 (exact public offering price) on July 1, closing day of NVCT's $100M public offering. Likely directed-share participation at offer price. Current price $19.57 (-2.2% from buy price). Adds to cluster signal alongside Mosseri's larger open-market buy below the offer price. | ||||||
| Jul 2, 2026 | Marlio Charles Mosseri10% Owner | $916K | Added | |||
| Bought 50,000 shares at weighted avg $18.32 on June 30 (ranging $18.29–$18.32), one day before the company's $100M public offering closed at $20/share. True open-market purchase below offering price. Serial accumulator: 25 buys, 0 sells over 5 years. Now $19.52 (+6.5% since buy). | ||||||
| Jul 2, 2026 | Ron BentsurChairman & CEO | $250K | Added | |||
| Bought 12,500 shares at $20.00/share on June 30 — exactly the public offering price announced June 29. Likely directed-share participation in the $100M offering, not pure open-market. CEO commitment buy alongside the deal. Now $19.52 (−2.4% since buy). Post-transaction holdings: 3,688,424 shares. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.